<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7049676\results\search\drugs\results.xml">
  <result pre="EASL European Association for the Study of the Liver ETV" exact="entecavir" post="HBeAg hepatitis B e antigen HBsAg hepatitis HBV surface"/>
  <result pre="PWID people who inject drugs SVR sustained virologic response TAF" exact="tenofovir" post="alafenamide TDF tenofovir disoproxil fumarate Viral hepatitis continues to"/>
  <result pre="inject drugs SVR sustained virologic response TAF tenofovir alafenamide TDF" exact="tenofovir" post="disoproxil fumarate Viral hepatitis continues to contribute to the"/>
  <result pre="of decompensation. In patients with eGFR &amp;lt; 30 mL/min/1.73 m2," exact="sofosbuvir" post="should only be used if no alternative treatment approved"/>
  <result pre="(C) John Wiley &amp;amp; Sons, Ltd, Since the approval of" exact="telaprevir" post="and boceprevir in 2011 with SVR rates of 65%"/>
  <result pre="Wiley &amp;amp; Sons, Ltd, Since the approval of telaprevir and" exact="boceprevir" post="in 2011 with SVR rates of 65% to 75%,"/>
  <result pre="high�?fold resistance variants to NS5A Severe renal impairment GT3: Add" exact="sofosbuvir" post="for PEG/RBV experienced with compensated cirrhosis Not for decompensated"/>
  <result pre="cirrhosis 24�?week duration and add RBV for decompensated cirrhosis with" exact="sofosbuvir" post="failure Following liver transplant with/without cirrhosis (compensated or decompensated)"/>
  <result pre="lung and 8 heart transplants) who received 4 weeks of" exact="sofosbuvir" post="and velpatasvir immediately after transplantation. The authors found that,"/>
  <result pre="long�?term (up to 8 years) rates of HBV resistance to" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)."/>
  <result pre="to 8 years) rates of HBV resistance to entecavir (ETV)," exact="tenofovir" post="disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). Thus, these"/>
  <result pre="HBV resistance to entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir" post="alafenamide (TAF). Thus, these three antiviral drugs have become"/>
  <result pre="treatments Abbreviations: eGFR, estimated glomerular filtration rate; ETV, entecavir; TAF," exact="tenofovir" post="alafenamide; TDF, tenofovir disoproxil fumarate. (C) John Wiley &amp;amp;"/>
  <result pre="estimated glomerular filtration rate; ETV, entecavir; TAF, tenofovir alafenamide; TDF," exact="tenofovir" post="disoproxil fumarate. (C) John Wiley &amp;amp; Sons, Ltd, Future"/>
  <result pre="alpha. Additionally, additional NAs are currently in development, including other" exact="tenofovir" post="prodrugs besifovir and metacavir.63 Unfortunately, even though NAs effectively"/>
  <result pre="24PoordadF, SchiffER, VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with" exact="sofosbuvir" post="and ribavirin for hepatitis C virus infection with advanced"/>
  <result pre="VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with sofosbuvir and" exact="ribavirin" post="for hepatitis C virus infection with advanced cirrhosis or"/>
  <result pre="FlisiakR, TrinhH, PetersenJ, GurelS, et al. Long term treatment with" exact="tenofovir" post="disoproxil fumarate for chronic hepatitis B infection is safe"/>
  <result pre="SetoWK, LimY�?S, FungS, MarcellinP, et al. 96 weeks treatment of" exact="tenofovir" post="alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus"/>
  <result pre="MarcellinP, et al. 96 weeks treatment of tenofovir alafenamide vs." exact="tenofovir" post="disoproxil fumarate for hepatitis B virus infection. J Hepatol2018;68:672�?681.29756595"/>
 </snippets>
</snippetsTree>
